Maria C Denis, Ph.D
Chief Executive Officer

Dr Denis has a B.Sc. in Microbiology from the University of Massachusetts, USA and a PhD in Immunology from Tufts Medical School, USA focusing on the role of post-transcriptional regulation in IL2 bioactivity. MD has more than fifteen years of research experience in academia and industry with sound expertise in immunology, inflammation, autoimmunity, imaging and pre-clinical drug evaluation. From 2001-2003 MD held a joint postdoctoral fellow position at Harvard Medical School in the laboratories of Drs D. Mathis and C. Benoist (Joslin Diabetes Center) and Dr. R. Weissleder (Massachusetts General Hospital), Boston, USA. Her post-doctoral work resulted in the development of a method of imaging pancreatic inflammation in mouse models of type 1 diabetes, a diagnostic tool that has since been translated to the clinic. Her work was supported by an NIH F32 fellowship and an NRSA training fellowship grant. In 2003 Dr. Denis joined the laboratory of Dr G. Kollias at BSRC Al.Fleming, Vari-Athens, Greece, to study the role of TNF-TNFR2 signaling in the pathogenesis of EAE, work supported by a Marie Curie Incoming International Fellowship.

In September 2009, Dr. Denis joined Biomedcode's Scientific Management Team first as Head of Preclinical Services and since March 2010 as Chief Executive Officer.

Niki Karagianni, Ph.D
Chief Scientific Officer

Dr. Niki Karagianni obtained her Bachelor's degree in Chemistry from the Athens University and completed her Ph.D. in the Biology Department of the same University on the role of glucocorticoid receptors in the transcriptional regulation of early response genes. She joined as postdoctoral fellow the Tumour Immunology Programme, at DKFZ, Heidelberg, Germany, where she worked on the generation of transgenic and knockout mice as well as gene transfer approaches targeting undifferentiated cells, Prof. D. Paulin’s lab in University of Paris VII and Prof. H.von Boehmer’s lab in the Faculty of Medicine, Necker Enfants-Malades working with in vivo gene delivery using retroviral and adenoviral vectors as well as the generation of conditional knockout and transgenic mice. In 2003 Dr. Karagianni joined the Laboratory of Dr. G. Kollias at BSRC Fleming, Vari-Athens, Greece, to work on the generation and characterization of “humanized” knockin, knockout and transgenic models, as well as on the development of anti-TNFR1 therapeutic approaches.

In September 2009, Dr. Karagianni joined Biomedcode's Scientific Management Team as the Head of R&D.

Ksanthi Kranidioti, MSc
R&D officer & Senior Study director

Ms Kranidioti has a BSc in Molecular Biology and Biotechnology from the University of Hull, UK and a MSc in Biochemical Pharmacology from the University of Southampton, UK. For more than 15 years she worked as research associate in the laboratory of Prof. G. Kollias initially at Pasteur Institute, Athens, Greece and afterwards in BSRC Al. Fleming, Greece studying the role of TNF and its receptors in pathogenic and physiological functions with a special focus in arthritis, IBD and multiple sclerosis.

In 2010 Ksanthi joined Biomedcode as a research assistant in the R&D department. Since July 2014 she serves as Biomedcode’s senior study director.